Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. WO 2025143118

    COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT D'UNE LÉSION DE LA MOELLE ÉPINIÈRE ET PROCÉDÉ DE PRODUCTION D'UN MODÈLE ANIMAL DE PRIMATE NON HUMAIN POUR UNE LÉSION DE LA MOELLE ÉPINIÈRE

    ASTELLAS PHARMA INC [JP] · Granted Thu Jul 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12350298

    Microbiome related immunotherapies

    Finch Therapeutics Holdings LLC · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12350120

    Gum-protecting and teeth-whitening strip and preparation method thereof

    Jiangxi Dentalbright Technology Co., Ltd. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12351579

    Compounds and uses thereof

    FOGHORN THERAPEUTICS INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12351574

    Selective ligands for modulation of GIRK channels

    Northwestern University · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12351850

    Methods of producing full-length antibodies using E. coli

    Sutro Biopharma, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12350250

    Aggrelytes for treating ocular conditions

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12350242

    Binge behavior regulators

    CLEARMIND MEDICINE INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12350245

    Stable oral suspensions of baclofen

    ANI Pharmaceuticals, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12350258

    Compositions and methods for treatment of skin-related diseases and promoting dermatological health

    Script Essentials, LLC · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12350270

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12350274

    Nucleotide analogs

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12350313

    Activin receptor type IIa variants and methods of use thereof

    Keros Therapeutics, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12350338

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12350343

    Bicyclic peptide ligands specific for MT1-MMP

    BicycleTx Limited · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12350374

    Fabrication of protein-encapsulating microgels

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12350383

    Cationic lipids containing silicon

    ARBUTUS BIOPHARMA CORPORATION · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12351590

    Pyrrolopyrimidine compound and use thereof

    Medshine Discovery Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12351581

    Compounds for FGFR inhibition

    Cogent Biosciences, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12351877

    Systems and methods for determining a treatment course of action

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12351653

    Pharmaceutical compositions comprising novel cyclic peptides

    LISATA THERAPEUTICS, INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12351649

    Antibodies to oxidation-specific epitopes

    The Regents of the University of California · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12350399

    Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

    The Regents of the University of California · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12351609

    Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload

    The Board of Regents of the University of Texas System · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12350510

    Magnetic microwires for energy-transporting biomedical applications

    Northwestern University · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12351824

    Method for producing natural killer cells from pluripotent stem cells

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12351614

    CLEC9A-based chimeric protein complexes

    Orionis Biosciences, Inc · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12351587

    Bicyclic compound as RIP-1 kinase inhibitor and application thereof

    Medshine Discovery Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12351560

    Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12350262

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12351625

    Therapeutic antibodies against osteopontin

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12351638

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    LEGEND BIOTECH USA INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12351644

    Anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12351633

    PD-1 and PD-L1 binding agents

    Orionis Biosciences, Inc · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12351611

    Molecules for organelle-specific protein delivery

    Larimar Therapeutics, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12350322

    Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation

    United Biomedical, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12350318

    Combination therapy to treat brain cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12351561

    Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Theravance Biopharma R&D IP, LLC · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12351834

    Compositions and methods for the treatment of ornithine transcarbamylase deficiency

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12351839

    Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

    Precision BioSciences, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 2025222125

    Anti-FGFR2b Antibodies, Conjugates and Methods of Use

    BEIGENE LTD [KY] · Granted Thu Jul 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. WO 2025146482

    FINÉRÉNONE DESTINÉE À ÊTRE UTILISÉE DANS UN PROCÉDÉ DE PRÉVENTION OU DE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE CHEZ UN PATIENT RECEVANT UN INHIBITEUR DE CYP3A4 OU UN INDUCTEUR DE CYP3A4

    BAYER AG [DE] · Granted Thu Jul 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. WO 2025146444

    DAROLUTAMIDE EN COMBINAISON AVEC DES INHIBITEURS DE BRAF ET DE MEK POUR LE TRAITEMENT D'UN MÉLANOME

    BAYER AG [DE] · Granted Thu Jul 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. WO 2025147499

    LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE

    ABBVIE INC [US] · Granted Thu Jul 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12359220

    Guided magnetic nanostructures for targeted and high-throughput intracellular delivery

    The Regents of the University of California · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12359204

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.